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A BS TR AC T
BACKGROUND
Vitreomacular adhesion can lead to pathologic traction and macular hole. The standard 
treatment for severe, symptomatic vitreomacular adhesion is vitrectomy. Ocriplasmin 
is a recombinant protease with activity against fibronectin and laminin, components 
of the vitreoretinal interface.
METHODS
We conducted two multicenter, randomized, double-blind, phase 3 clinical trials to 
compare a single intravitreal injection of ocriplasmin (125 μg) with a placebo injec-
tion in patients with symptomatic vitreomacular adhesion. The primary end point 
was resolution of vitreomacular adhesion at day 28. Secondary end points were total 
posterior vitreous detachment and nonsurgical closure of a macular hole at 28 days, 
avoidance of vitrectomy, and change in best-corrected visual acuity.
RESULTS
Overall, 652 eyes were treated: 464 with ocriplasmin and 188 with placebo. Vitreo-
macular adhesion resolved in 26.5% of ocriplasmin-injected eyes and in 10.1% of 
placebo-injected eyes (P<0.001). Total posterior vitreous detachment was more prev-
alent among the eyes treated with ocriplasmin than among those injected with 
placebo (13.4% vs. 3.7%, P<0.001). Nonsurgical closure of macular holes was 
achieved in 40.6% of ocriplasmin-injected eyes, as compared with 10.6% of placebo-
injected eyes (P<0.001). The best-corrected visual acuity was more likely to improve 
by a gain of at least three lines on the eye chart with ocriplasmin than with placebo. 
Ocular adverse events (e.g., vitreous floaters, photopsia, or injection-related eye pain 
— all self-reported — or conjunctival hemorrhage) occurred in 68.4% of ocriplasmin-
injected eyes and in 53.5% of placebo-injected eyes (P<0.001), and the incidence of 
serious ocular adverse events was similar in the two groups (P = 0.26).
CONCLUSIONS
Intravitreal injection of the vitreolytic agent ocriplasmin resolved vitreomacular 
traction and closed macular holes in significantly more patients than did injection 
of placebo and was associated with a higher incidence of ocular adverse events, 
which were mainly transient. (Funded by ThromboGenics; ClinicalTrials.gov num-
bers, NCT00781859 and NCT00798317.)
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The human vitreous body is bounded posteriorly by the retina and is variably ad-herent to it. Collagen fibrils forming the 
posterior vitreous cortex are firmly attached at the 
macula, the central part of the retina where visual 
acuity is best, and are connected to its internal lim-
iting membrane by means of a biochemical glue 
composed of proteoglycans, including laminin and 
fibrinectin.1-4 With aging, the gel-like vitreous 
progressively liquefies and vitreoretinal adhesions 
weaken, leading to separation of the vitreous from 
the retina, or posterior vitreous detachment.5-7
Vitreomacular adhesion is observed after partial 
posterior vitreous detachment, when a portion 
of the posterior vitreous remains attached to the 
macula. When traction increases in response to 
anteroposterior forces, tangential forces, or both, 
the adhesion may cause vitreomacular traction and 
become symptomatic. Symptoms typically include 
metamorphopsia and blurring of visual acuity with 
central visual-field defects. Vitreomacular traction 
can lead to macular distortion and edema and to 
the formation of macular holes.8 It has been sug-
gested that vitreomacular adhesion may play a role 
in the progression of diabetic retinopathy and age-
related macular degeneration.1,9-12 Vitrectomy is 
the only treatment for vitreomacular traction and 
macular holes, and because it poses certain risks 
(infection, retinal detachment, hemorrhage, and 
cataract), it is usually withheld until loss of vi-
sion has become clinically significant.
Vitreolysis involving an enzyme that has activ-
ity against the molecular substrates responsible 
for vitreomacular adhesion is a potential nonsur-
gical, biologic approach to the treatment of this 
disorder. Substances directed against biochemical 
components of the vitreomacular interface, such as 
chondroitinase, dispase, and hyaluronidase, have 
been tested but were abandoned because of insuf-
ficient clinical efficacy, complications, or both.13-15 
Plasmin and a truncated form of plasmin, ocriplas-
min (formerly microplasmin), have been shown 
to be effective in ex vivo studies of vitreolysis in 
animals and humans.16-18 Such an approach to 
symptomatic vitreomacular adhesion could allow 
nonsurgical intervention, treatment at an earlier 
stage of the disease, or both, which would prob-
ably result in better outcomes.1,7,13-15,19
Ocriplasmin is a truncated form of the human 
serine protease plasmin and has proteolytic activ-
ity against fibronectin and laminin, two major 
components of the vitreoretinal interface. Results 
of preclinical and clinical studies have suggested 
that ocriplasmin can induce vitreous liquefaction 
and separation from the retina.17,18,20 Phase 2 stud-
ies have shown that intravitreal injection of a 
single 125-μg dose of ocriplasmin or up to three 
injections of 125 μg each given monthly can in-
duce the resolution of vitreomacular traction and 
closure of macular holes without causing serious 
adverse events.1,21
Me thods
STUDY DESIGN AND OVERSIGHT
We performed two multicenter, randomized, 
double-blind, placebo-controlled, phase 3 studies 
(TG-MV-006 and TG-MV-007, hereafter called study 
006 and study 007) to test the efficacy and safety 
of a single intravitreal injection of ocriplasmin. 
Patients were randomly assigned to intravitreal in-
jection of either ocriplasmin or placebo. Owing to 
a specific recommendation by the Food and Drug 
Administration, the ratio of randomized assign-
ments to ocriplasmin and placebo in study 006 was 
changed to 2:1, and the randomization ratio in 
study 007 was 3:1 from the outset. Otherwise, the 
study protocols were identical. In study 006, en-
rollment began on December 23, 2008, and was 
completed on September 4, 2009. In study 007, en-
rollment began on December 22, 2008, and was 
completed on September 17, 2009. The studies were 
approved by the institutional review board or in-
dependent ethics committee at each participating 
site, and we obtained written informed consent 
from all patients before they were enrolled.
Both trials were designed, coordinated, and 
sponsored by ThromboGenics. The data were gath-
ered independently by the Microplasmin for In-
travitreous Injection — Traction Release without 
Surgical Treatment (MIVI-TRUST) study groups 
and were analyzed by contract research organiza-
tions paid by ThromboGenics. The authors wrote 
the manuscript and made the decision, in consul-
tation with ThromboGenics, to submit it for pub-
lication. The authors attest that the studies were 
performed in accordance with the protocols, in-
cluding the statistical analysis plans, available with 
the full text of this article at NEJM.org. The au-
thors vouch for the accuracy and completeness of 
the reported results and for the fidelity of this re-
port to the study protocols.
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INCLUSION AND EXCLUSION CRITERIA
Patients were eligible for the study if they were at 
least 18 years of age and had focal vitreomacular 
adhesion, defined as vitreous adhesion to the mac-
ula within a 6-mm central retinal field surrounded 
by elevation of the posterior vitreous cortex, as seen 
on optical coherence tomography (OCT), and a 
best-corrected visual acuity of 20/25 or less in the 
study eye and 20/800 or more in the nonstudy eye, 
according to the Early Treatment Diabetic Reti-
nopathy Study (ETDRS) acuity chart. Patients were 
excluded if they had proliferative diabetic retinopa-
thy, neovascular age-related macular degeneration, 
retinal vascular occlusion, aphakia, high myopia 
(more than −8 diopters), uncontrolled glaucoma, a 
macular hole greater than 400 μm in diameter, 
vitreous opacification, lenticular or zonular insta-
bility, or a history of retinal detachment in either 
eye. Additional exclusion criteria were prior vitrec-
tomy, prior laser photocoagulation of the macu-
la, and treatment with ocular surgery, intravitreal 
injection, or retinal laser photocoagulation in the 
previous 3 months. The presence of an epiretinal 
membrane was not a criterion for exclusion.
TREATMENT
Patients randomly assigned to the ocriplasmin 
group received an intravitreal injection of ocri-
plasmin (125 μg in a 0.10-ml volume) drawn from 
a vial containing ocriplasmin into which 0.75 ml 
of commercial saline had been injected (1875 μg of 
ocriplasmin in a 0.75-ml drug vehicle). Patients 
randomly assigned to placebo received an intra-
vitreal injection of 0.10 ml of the identical drug 
vehicle diluted with saline, the method used be-
ing the same as that used to prepare ocriplasmin. 
Assessments were made at baseline, on the day of 
injection, and on days 7, 14, 28, 90, and 180 after 
the injection. Investigators could proceed to rec-
ommend vitrectomy at any time if the underlying 
condition deteriorated, if the best-corrected visual 
acuity in the study eye worsened by more than 
two lines on the eye chart, or if the underlying 
condition had not improved within 4 weeks after 
the injection.
ASSESSMENTS
Assessments included a complete ophthalmic ex-
amination (measurement of best-corrected visual 
acuity, manifest refraction, and intraocular pres-
sure; slit-lamp examination; and ophthalmoscopy 
with pupillary dilation), B-scan ultrasonography 
to evaluate the status of the posterior vitreous 
cortex, OCT to document the status of vitreo-
macular adhesion and the presence or absence of 
a macular hole, fundus photography, and fluo-
rescein angiography. Patients completed the self-
administered National Eye Institute Visual Func-
tioning Questionnaire–25 (VFQ-25) (August 2000 
version, translated into the native languages of 
the patients),22,23 which assesses visual function 
and general health on a scale from 0 to 100, with 
a score of 100 indicating optimal function and 
health.
Best-corrected visual acuity was reported as 
the number of letters correctly read by the pa-
tient on an ETDRS chart at 4 m. OCT measure-
ments obtained with the use of the time-domain 
Stratus device (Zeiss) were mandatory. In addition, 
spectral-domain OCT images were obtained when 
the devices required for such images were avail-
able. Trained readers at a central reading center 
(Duke University OCT Reading Center, Durham, 
NC) who were unaware of the group assignments 
evaluated the OCT images. All ultrasonographic 
studies were standardized and performed by 
certified technicians who underwent special train-
ing for the study. Staging of posterior vitreous de-
tachment was based on dynamic ultrasonograph-
ic evaluation and performed by an investigator 
who was unaware of the group assignments (see 
Table S1 in the Supplementary Appendix, avail-
able at NEJM.org).24,25 Cataracts were graded on 
the basis of standardized photographs according 
to the methods used in the Age-Related Eye Dis-
ease Study 2008 system.26
STUDY END POINTS
The primary end point was the percentage of eyes 
with nonsurgical resolution of vitreomacular ad-
hesion at day 28, as determined by the OCT eval-
uation obtained from the central reading center. 
The main secondary end point was the percentage 
of eyes with total posterior vitreous detachment 
at day 28, as determined by the investigator from 
standardized B-scan ultrasonograms. Predeter-
mined secondary end points included the need 
for vitrectomy, closure of a macular hole, a gain 
of three or more lines in the assessment of best-
corrected visual acuity without vitrectomy, and 
change from baseline in best-corrected visual 
acuity and VFQ-25 score at 6 months.23,27
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STATISTICAL ANALYSIS
Assuming that the rate of the primary end point 
was 27.5% in the ocriplasmin group and 10.0% in 
the placebo group, we determined that a sample 
of 320 patients would provide more than 90% pow-
er to detect a significant difference at a two-sided 
alpha level of 0.05. For all planned and exploratory 
analyses, statistical significance was set at an al-
pha level of 0.05. All statistical tests and confi-
dence intervals were two-sided. Statistical analysis 
of the primary and secondary end points was per-
formed on the combined data from both trials 
(i.e., all patients who underwent randomization, 
according to the intention-to-treat principle) by 
carrying the last observation forward as a con-
servative approach to impute any missing data.
For binary end points, group comparisons in 
the individual studies were carried out with the use 
of Fisher’s exact test. Treatment effects are ex-
pressed as odds ratios and corresponding exact 
95% confidence intervals. Homogeneity of the 
odds ratios across the two studies was assessed by 
means of a Breslow–Day test. Results were com-
bined and analyzed by means of a Cochran–
Mantel–Haenszel test and were stratified accord-
ing to the study. We derived common odds ratios, 
with their associated exact 95% confidence in-
tervals, with the use of a logistic-regression 
model that included factors for study group and 
for study.
We compared changes in best-corrected visual 
acuity and VFQ-25 scores between the two study 
groups with the use of an analysis-of-variance 
model, adjusted with a factor for baseline best-
corrected visual acuity and VFQ-25 score. For the 
combined analysis, a mixed-model analysis of 
variance was used, including a fixed effect for 
study group and a random effect for study. For the 
safety analyses, patients were evaluated according 
to the study medication they actually received.
R esult s
PATIENTS
In total, 652 patients were enrolled; 464 patients 
were randomly assigned to receive an intravitreal 
ocriplasmin injection and 188 to receive a place-
bo injection. The study groups had similar demo-
graphic and baseline disease characteristics, with 
two exceptions: pseudophakia was more common 
in the ocriplasmin group than in the placebo group 
(37.1% vs. 28.2%), and there were more women in 
the ocriplasmin group than in the placebo group 
(67.7% vs. 61.2%) (Table S2 in the Supplementary 
Appendix).
END POINTS
The primary end point, the proportion of patients 
with nonsurgical resolution of vitreomacular adhe-
sion on OCT at day 28, was significantly higher 
with ocriplasmin than with placebo in each of the 
two studies (P = 0.003 in study 006 and P<0.001 in 
study 007). We found no significant evidence for 
heterogeneity of treatment effects between the 
two studies (P = 0.23). For the combined studies, 
the odds ratio for intervention was 3.28 on the 
primary end point (95% confidence interval [CI], 
1.93 to 5.84; P<0.001) (Table 1). Table 1 shows the 
treatment effects on the primary and secondary 
end points in the two individual studies and for the 
combined data. The difference between the ocri-
plasmin and placebo groups was significant for 
all prespecified end points in the combined anal-
yses. Overall, 26.5% of the patients in the ocriplas-
min group reached the primary end point (reso-
lution of vitreomacular adhesion), as compared 
with 10.1% of those in the placebo group (Fig. 
1A). The between-group difference in the per-
centage of eyes with resolution of vitreomacular 
adhesion reached significance at day 7, the day of 
the first study visit after the injection (odds ratio 
for nonsurgical resolution with ocriplasmin, 5.20; 
95% CI, 2.53 to 12.07; P<0.001), and the percent-
age remained higher with ocriplasmin at all sub-
sequent visits through month 6 (Fig. 1A).
The magnitude of the effect of ocriplasmin on 
the primary end point varied according to lens 
status. Among phakic eyes, 34.2% in the ocriplas-
min group versus 12.6% in the placebo group had 
resolution of vitreomacular adhesion (odds ratio, 
3.75; 95% CI, 2.09 to 7.07; P<0.001); among eyes 
with pseudophakia, 13.4% in the ocriplasmin 
group versus 3.8% in the placebo group had reso-
lution of vitreomacular adhesion (odds ratio, 3.96; 
95% CI, 0.92 to 35.89; P = 0.051). Resolution of 
vitreomacular adhesion was achieved in 18.7% 
of men who received ocriplasmin versus 5.5% of 
those who received placebo (odds ratio, 3.83; 95% 
CI, 1.25 to 15.75; P = 0.01) and in 30.3% of women 
who received ocriplasmin versus 13.0% of those 
who received placebo (odds ratio, 2.94; 95% CI, 
1.60 to 5.76; P<0.001).
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A prespecified subgroup analysis based on the 
presence or absence of an epiretinal membrane 
showed that among patients without an epiretinal 
membrane, 37.4% in the ocriplasmin group had 
nonsurgical resolution of vitreomacular adhesion, 
as compared with 14.3% in the placebo group 
(odds ratio, 3.79; 95% CI, 2.09 to 7.22; P<0.001) 
(Fig. 1B). Among patients with an epiretinal 
membrane, resolution of vitreomacular adhesion 
occurred in 8.7% of those in the ocriplasmin 
group as compared with 1.5% of those in the 
placebo group (odds ratio, 6.20; 95% CI, 0.93 to 
265.068; P = 0.046).
Total posterior vitreous detachment at day 28 
was noted on ultrasonography in 13.4% of eyes 
injected with ocriplasmin, as compared with 3.7% 
of eyes injected with placebo (odds ratio, 4.27; 
95% CI, 1.89 to 11.32; P<0.001) (Fig. 2A). Non-
surgical closure of a macular hole by day 28 was 
achieved in 40.6% of eyes injected with ocriplas-
min, as compared with 10.6% of eyes injected with 
placebo (odds ratio, 5.94; 95% CI, 2.09 to 21.01; 
P<0.001) (Fig. 2B, and Fig. S1 in the Supplemen-
tary Appendix), and the percentage remained 
higher with ocriplasmin at the end of the study 
(40.6%, vs. 17.0% with placebo; odds ratio, 3.45; 
95% CI, 1.40 to 9.49; P = 0.004).
During the studies, some patients underwent 
vitrectomy, in most instances to treat persistent 
vitreomacular adhesion. At 6 months, fewer pa-
Table 1. Effect of Treatment with Ocriplasmin on the Primary and Prespecified Secondary End Points in Studies 006 
and 007 and the Combined Results.
Variable Placebo Ocriplasmin Odds Ratio (95% CI)* P Value
no. of events/total no. of patients (%)
Resolution of vitreomacular adhesion at day 28 (homogeneity of treatment effect, P = 0.23)
Study 006 14/107 (13.1) 61/219 (27.9) 2.56 (1.32–5.24) 0.003
Study 007 5/81 (6.2) 62/245 (25.3) 5.13 (1.97–17.00) <0.001
Combined data 19/188 (10.1) 123/464 (26.5) 3.28 (1.93–5.84) <0.001
Total posterior vitreous detachment at day 28 (homogeneity of treatment effect, P = 0.07)
Study 006 7/107 (6.5) 36/219 (16.4) 2.80 (1.17–7.74) 0.01
Study 007 0/81 (0) 26/245 (10.6) 13.55 (2.35–∞) <0.001
Combined data 7/188 (3.7) 62/464 (13.4) 4.27 (1.89–11.32) <0.001
Closure of macular hole at day 28 (homogeneity of treatment effect, P = 0.74)
Study 006 4/32 (12.5) 25/57 (43.9) 5.37 (1.58–23.84) 0.002
Study 007 1/15 (6.7) 18/49 (36.7) 7.94 (1.04–362.47) 0.03
Combined data 5/47 (10.6) 43/106 (40.6) 5.94 (2.09–21.01) <0.001
Improvement in visual acuity ≥3 lines at month 6 (homogeneity of treatment effect, P = 0.28)
Study 006 9/107 (8.4) 28/219 (12.8) 1.59 (0.70–4.00) 0.27
Study 007 3/81 (3.7) 29/245 (11.8) 3.48 (1.03–18.35) 0.03
Combined data 12/188 (6.4) 57/464 (12.3) 2.09 (1.08–4.41) 0.02
Vitrectomy at month 6 (homogeneity of treatment effect, P = 0.83)
Study 006 31/107 (29.0) 45/219 (20.5) 0.64 (0.36–1.12) 0.10
Study 007 19/81 (23.5) 37/245 (15.1) 0.58 (0.30–1.15) 0.09
Combined data 50/188 (26.6) 82/464 (17.7) 0.61 (0.40–0.94) 0.02
Any ocular adverse event (homogeneity of treatment effect, P = 0.73)
Study 006 62/106 (58.5) 159/220 (72.3) 1.85 (1.10–3.09) 0.02
Study 007 38/81 (46.9) 159/245 (64.9) 2.09 (1.22–3.60) 0.006
Combined data 100/187 (53.5) 318/465 (68.4) 1.96 (1.36–2.82) <0.001
Any ocular serious adverse event (homogeneity of treatment effect, P = 0.34)
Study 006 11/106 (10.4) 21/220 (9.5) 0.91 (0.40–2.18) 0.84
Study 007 9/81 (11.1) 15/245 (6.1) 0.52 (0.20–1.42) 0.15
Combined data 20/187 (10.7) 36/465 (7.7) 0.72 (0.39–1.36) 0.26
* CI denotes confidence interval.
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tients in the ocriplasmin group than in the placebo 
group had undergone vitrectomy (17.7% vs. 26.6%; 
odds ratio, 0.61; 95% CI, 0.40 to 0.94; P = 0.02).
In the total population of patients, an improve-
ment in best-corrected visual acuity of three or 
more lines on the eye chart was achieved in 12.3% 
of eyes injected with ocriplasmin, as compared 
with 6.4% of eyes injected with placebo (odds 
ratio, 2.09; 95% CI, 1.08 to 4.41; P = 0.02) (Fig. 
S2A in the Supplementary Appendix). In eyes not 
treated with vitrectomy, the corresponding values 
were 9.7% versus 3.7% (odds ratio, 2.89 95% CI, 
1.26 to 7.76; P = 0.008).
Post hoc subgroup analyses stratified by base-
line best-corrected visual acuity revealed that at 
month 6, a gain of at least three lines was more 
likely among patients with poorer vision (i.e., base-
line best-corrected visual acuity <20/50) than in 
those with better vision (i.e., baseline best-correct-
ed visual acuity of 20/32 to 20/50 or of >20/32). 
Among patients with a baseline best-corrected 
visual acuity that was worse than 20/50, 25.1% of 
those treated with ocriplasmin had a gain of three 
or more lines, as compared with 11.4% of those 
given placebo (P = 0.01). Among patients with a 
baseline best-corrected visual acuity that was bet-
ter than 20/50, the proportion of eyes that gained 
three or more lines did not differ significantly 
between the ocriplasmin and placebo groups (Fig. 
S2B in the Supplementary Appendix). In all sub-
groups combined, the mean change, as measured 
by the number of ETDRS letters gained or lost, was 
not significant (treatment difference, 1.1; 95% CI, 
−0.8 to 2.9; P = 0.27).
The mean change in the score on the general 
quality-of-life VFQ-25 vision subscale was an 
increase of 6.1 points in the ocriplasmin group 
and an increase of 2.1 points in the placebo 
group (difference, 4.0 points; 95% CI, 1.2 to 6.8; 
P = 0.006).22,23 The mean change in the overall 
composite score was an increase of 3.4 points in 
the ocriplasmin group and an increase of 0.7 
points in the placebo group (difference, 2.7 points; 
95% CI, 0.7 to 4.8; P = 0.007).
SAFETY
The proportion of patients who had any ocular 
adverse event in the study eye was 68.4% in the 
ocriplasmin group and 53.5% in the placebo group 
(P<0.001) (Table 2). This difference was driven 
primarily by adverse events known to be associ-
ated with vitreous detachment. Most of the ad-
verse events were transient and mild in severity. 
The most common ocular adverse event in the 
study eye was vitreous floaters, reported by 16.8% 
of patients in the ocriplasmin group and 7.5% 
of those in the placebo group (Table 2). The in-
cidence of any serious ocular adverse event in 
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Figure 1. Nonsurgical Resolution of Vitreomacular Adhesion (VMA) 
with Ocriplasmin versus Placebo to Day 180.
Panel A shows the results in study 006 and study 007 and in the combined 
studies. Black symbols represent the ocriplasmin group, and blue symbols 
the placebo group. Panel B shows the results in patients with and in those 
without an epiretinal membrane (ERM).
The New England Journal of Medicine 
Downloaded from nejm.org on March 9, 2021. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;7 nejm.org august 16, 2012612
compared with 10.7% in the placebo group 
(P = 0.26).
Retinal tears or detachments were diagnosed in 
1.9% of the patients given ocriplasmin, as com-
pared with 4.3% of those given placebo (P = 0.11). 
Retinal tears occurred in six of the ocriplasmin-
injected eyes and in five of the placebo-injected 
eyes. Most of these tears occurred during vitrec-
tomy, which was performed for vitreomacular 
traction or macular holes, and were successfully 
treated intraoperatively. Two retinal tears with 
detachment occurred before any surgery in the 
ocriplasmin group and were treated by means of 
vitrectomy, with successful retinal reattachment. 
One of these eyes had a best-corrected visual acu-
ity at baseline of 52 ETDRS letters and had recov-
ery to 44 at 6 months; the other eye, with a base-
line best-corrected visual acuity of 70 ETDRS 
letters, had recovery to 62.
The injections caused no acute cataracts. We 
observed progression of cataracts in 8.2% of pha-
kic eyes injected with ocriplasmin and in 11.9% 
of phakic eyes injected with placebo (P = 0.32). 
Among patients who did not undergo vitrectomy, 
the proportion of patients with cataract progres-
sion was similar in the ocriplasmin and placebo 
groups (4.8% and 5.2%, respectively; P = 0.97). 
No cases of endophthalmitis were observed.
Discussion
Our data support the finding that intravitreal in-
jection of ocriplasmin leads to resolution of vitreo-
macular traction, induction of posterior vitreous 
detachment, and closure of a macular hole in some 
cases. The incidence of vitrectomy was lower 
among the patients who received ocriplasmin 
than among those who received placebo. A sham 
injection would have provided a better compari-
son with the natural history of the disease pro-
cess than that provided by the group of patients 
who received a placebo, which was chosen to 
control for the effect of an intravitreal injection.
The main visual symptom of vitreomacular 
traction and macular holes is decreased visual acu-
ity. Although more patients in the ocriplasmin 
group than in the placebo group had increased 
visual acuity (defined as a gain of three or more 
lines of letters) and reported an improved quality 
of life, the gains were modest. Subgroup analysis 
suggests that the reason for this finding may be 
that we included patients with relatively good vi-
sual acuity (mean baseline acuity, 64 ETDRS let-
ters; Snellen equivalent, 20/50), creating a ceiling 
effect whereby only a limited number of patients 
had sufficiently poor vision to be able to gain 
three or more lines (Fig. S2B in the Supplemen-
tary Appendix). In more general terms, this pos-
sibility points to a limitation of the study: the 
visual acuity of the patients, with the exception 
of those with macular holes, was better than that 
of patients for whom vitrectomy would typically 
be recommended for the treatment of vitreomacu-















































































































































































Figure 2. Analyses of Secondary End Points at Day 28.
Panel A shows the percentage of patients with total posterior vitreous  
detachment (PVD), and Panel B shows the percentage of patients with  
closure of macular holes.
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We observed increasing lens opacification more 
often in the placebo group than in the ocriplasmin 
group, presumably because a higher proportion of 
eyes in the placebo group underwent vitrectomy. 
Retinal tears and detachment developed in two 
eyes after injection of the drug, presumably as a 
complication of pharmacologically induced poste-
rior vitreous detachment, and these complications 
were successfully treated with vitrectomy. Over-
all, more eyes in the placebo group than in the 
ocriplasmin-treated group had retinal tears and 
detachment, as reflected by a higher proportion 
of subjects in the placebo group who required 
vitrectomy.
Cataract surgery with or without subsequent 
posterior capsulotomy often induces posterior vit-
reous detachment soon after the procedure.28,29 
In this study, any intraocular procedure performed 
within 3 months before enrollment was an exclu-
sion criterion, reducing the odds that lens status 
would influence the study outcome. We observed 
a weak, nonsignificant effect of the intervention on 
pseudophakic eyes, as compared with its effect on 
phakic eyes. This may be due to potentially tighter 
vitreoretinal adhesion in pseudophakic eyes with-
out posterior vitreous detachment, as suggested 
by the fact that cataract surgery did not detach the 
vitreous.30 The reason for the greater apparent 
treatment effect in women than in men is also 
unclear; perhaps it is relevant to factors that make 
women more susceptible than men to vitreomac-
ular traction, especially macular-hole formation.
Vitreous manipulation effected through intra-
vitreal injection may occasionally result in a pos-
terior vitreous detachment,31,32 in which case, 
the placebo injection of 0.1 ml may have induced 
some treatment response. The superior therapeu-
tic effects of the ocriplasmin injection would then 
be indicative of an additional biologic effect of 
enzymatic vitreolysis over placebo.
The applicability of this study is limited by the 
exclusion of patients with severe myopia, apha-
kia, proliferative diabetic retinopathy, or neovas-
cular age-related macular degeneration.9 Further 
studies will be needed to explore the effect of 
enzymatic vitreolysis in these diseases.
In conclusion, our study shows that enzymatic 
vitreolysis represents a means to resolve vitreo-
macular traction and to close macular holes. 
Intravitreal injection of ocriplasmin was superior 
to injection of placebo in altering the vitreoretinal 
interface of affected eyes, although it was accom-
panied by some, mainly transient, ocular adverse 
events.
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